CA3067728A1 - Agent for the prophylactic and/or supportive therapeutic treatment of parkinson's disease - Google Patents

Agent for the prophylactic and/or supportive therapeutic treatment of parkinson's disease Download PDF

Info

Publication number
CA3067728A1
CA3067728A1 CA3067728A CA3067728A CA3067728A1 CA 3067728 A1 CA3067728 A1 CA 3067728A1 CA 3067728 A CA3067728 A CA 3067728A CA 3067728 A CA3067728 A CA 3067728A CA 3067728 A1 CA3067728 A1 CA 3067728A1
Authority
CA
Canada
Prior art keywords
salts
agent
esters
butyric acid
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067728A
Other languages
English (en)
French (fr)
Inventor
Horst Przuntek
Aiden Haghikia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3067728A1 publication Critical patent/CA3067728A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/05—Propionic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3067728A 2017-07-13 2018-07-13 Agent for the prophylactic and/or supportive therapeutic treatment of parkinson's disease Pending CA3067728A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102017115819.7 2017-07-13
DE102017115819.7A DE102017115819A1 (de) 2017-07-13 2017-07-13 Mittel zur prophylaktischen und/oder unterstützenden therapeutischen Behandlung von Morbus Parkinson
PCT/EP2018/069089 WO2019012108A1 (de) 2017-07-13 2018-07-13 Propion- und/oder buttersäure zur verwendung zur prophylaktischen und/oder unterstützenden therapeutischen behandlung von morbus parkinson

Publications (1)

Publication Number Publication Date
CA3067728A1 true CA3067728A1 (en) 2019-01-17

Family

ID=63108510

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067728A Pending CA3067728A1 (en) 2017-07-13 2018-07-13 Agent for the prophylactic and/or supportive therapeutic treatment of parkinson's disease

Country Status (10)

Country Link
US (2) US20200163914A1 (enExample)
EP (1) EP3651754B1 (enExample)
JP (1) JP7206223B2 (enExample)
KR (1) KR20200027976A (enExample)
CN (1) CN110996933A (enExample)
AU (2) AU2018298862A1 (enExample)
BR (1) BR112020000570A2 (enExample)
CA (1) CA3067728A1 (enExample)
DE (1) DE102017115819A1 (enExample)
WO (1) WO2019012108A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021048440A1 (en) 2019-09-13 2021-03-18 Basf Se Composition for the treatment of neurodegenerative diseases
CN111450238A (zh) * 2020-03-31 2020-07-28 上海交通大学医学院附属瑞金医院 骨钙素或丙酸在制备抗帕金森病药物中的应用
CN113332266A (zh) * 2021-06-10 2021-09-03 徐州医科大学 含丁酸的治疗与预防神经退行性疾病的药物及丁酸的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19503598A1 (de) * 1995-02-03 1996-08-08 Zuzana Dr Cully Verfahren zur fermentativen Herstellung von Propionsäure oder Buttersäure bzw. deren Salze
NL1009990C2 (nl) * 1998-09-02 2000-03-15 Sibeco Chemicals Voedingssupplement en werkwijze voor het vervaardigen van zulk voedingssupplement.
US20060105962A1 (en) * 2004-11-14 2006-05-18 Robinson Robert O A Tonic to maintain intestinal flora
WO2012095461A1 (de) * 2011-01-12 2012-07-19 Albert Daxer Getränk
EP3019181A4 (en) * 2013-07-09 2016-09-21 Puretech Ventures Llc COMPOSITIONS WITH COMBINATIONS OF BIOACTIVE MOLECULARS DERIVED FROM MICROBOTS FOR TREATING DISEASES
CN105055457A (zh) * 2015-08-06 2015-11-18 温州医科大学附属第二医院 一种防治阿尔茨海默病的药物及其制备方法和应用
DE102016103242A1 (de) * 2016-02-24 2017-08-24 Flexopharm Brain Gmbh & Co. Kg Mittel zur unterstützenden Immunmodulation
WO2017091072A1 (en) * 2015-11-27 2017-06-01 Birrbeheer B.V. Butyrate salts for use in inflammatory diseases
US11065217B2 (en) * 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders

Also Published As

Publication number Publication date
US20200163914A1 (en) 2020-05-28
EP3651754A1 (de) 2020-05-20
DE102017115819A1 (de) 2019-01-17
KR20200027976A (ko) 2020-03-13
AU2021273627A1 (en) 2021-12-16
BR112020000570A2 (pt) 2020-07-14
JP2020526485A (ja) 2020-08-31
CN110996933A (zh) 2020-04-10
WO2019012108A1 (de) 2019-01-17
US20220313634A1 (en) 2022-10-06
EP3651754C0 (de) 2025-04-30
AU2021273627B2 (en) 2024-01-25
EP3651754B1 (de) 2025-04-30
JP7206223B2 (ja) 2023-01-17
AU2018298862A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
US20220313634A1 (en) Agent for the prophylactic and/or supportive therapeutic treatment of parkinson's disease
US11471432B2 (en) Supporting immunomodulatory agent
TWI580427B (zh) Compositions for reducing body weight and reducing body fat, and pharmaceuticals and applications thereof
US11865091B2 (en) Supporting immunomodulatory agent
IL200929A (en) Magnesium compositions and uses thereof
TWI337066B (en) Dietary supplement
JPWO2006059730A1 (ja) 体脂肪減少用組成物
NO20001717L (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
US20130022673A1 (en) Enhancement of magnesium uptake in mammals
JP2012171899A (ja) 尿路感染症予防改善剤
US11596166B2 (en) Compositions and methods for treating aging and/or improving human health
KR20200022660A (ko) 혼합 추출물을 포함하는 지방간, 고지혈증 또는 비만 예방 또는 치료용 조성물
JP2009107987A (ja) 筋力向上剤
RU2670612C2 (ru) Композиция для предупреждения или лечения ожирения, содержащая α-липоевую кислоту и N-ацетилцистеин в качестве активных ингредиентов
US11458150B2 (en) Methylphosphinic acid compositions and methods for reducing aging
JP2010265186A (ja) 貧血予防用組成物
JPWO2009054360A1 (ja) 内臓脂肪特異的低減剤
JP2006213667A (ja) アスタキサンチン及び／又はそのエステルを有効成分とする筋萎縮改善剤及び飲食物
JP2004292355A (ja) 抗ストレス剤
JP2025513918A (ja) 新規なビフィドバクテリウムビフィダムｈｅｍ９７２菌株、及び前記菌株又はその培養物を含む腸内環境改善用組成物
EP4534079A1 (en) Composition based on inositol and oligomeric proanthocyanidins
JPH02142732A (ja) 肥満並びに肥満に関連する各種疾患の治療剤
Brendler et al. 13 Cranberry Proanthocyanidins
CN102526088A (zh) 维生素b12口服制剂的改进配方及用途
JP2009531306A5 (enExample)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220713

EEER Examination request

Effective date: 20220713

EEER Examination request

Effective date: 20220713

EEER Examination request

Effective date: 20220713

EEER Examination request

Effective date: 20220713

EEER Examination request

Effective date: 20220713